MARKET NEWS

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
Esperion Announces CLEAR Cardiovascular Outcomes Trial Meets Primary Endpoint
Gerresheimer to Expand Significantly in High Value Solutions & Further Accelerates its Sustainable Profitable Growth
Evonik Launches Plant-Based Squalene to Boost Vaccine Efficacy
Ocuphire Pharma Announces Submission of NDA for Eye Drops for Reversal of Mydriasis
RespireRx Enters Collaboration With National Institute for Neurological Disorders & Stroke to Advance its Lead GABAkine Toward Clinical Development

  FEATURED EDITORIAL

  COMPANY PROFILE

LATITUDE Pharmaceuticals is a leading-edge CDMO that provides innovative drug formulation development services and GMP manufacturing for early-phase clinical trials to the human and animal health industries. Founded in 2003, we have completed more than 1,000 client projects and have established a reputation for successfully formulating highly insoluble compounds – the most significant cause of drug development failure. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder

Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder

Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….

Summit Therapeutics Partners With Akeso Inc. in Deal for Up to  Billion to In-License Breakthrough Innovative Bispecific Antibody

Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..

Incannex Expands Intellectual Property Position Over IHL-42X

Incannex Expands Intellectual Property Position Over IHL-42X

Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….

Enzyvant Announces Merger With Altavant

Enzyvant Announces Merger With Altavant

Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges

Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments find swallowing tablets to be difficult. Orally disintegrating tablets (ODTs), which dissolve completely without chewing …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

WHITE PAPER - Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification

The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles can …

WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System

WHITE PAPER: Controlled Synthesis of Lipid Nanoparticles Using the Automated Nanoparticle System

ABSTRACT

Lipid nanoparticles (LNPs) are powerful carriers for the delivery of biotherapeutics and active pharmaceutical ingredients (APIs). They are attractive due to their size and biocompatibility, which are important factors when determining the efficacy of an encapsulated API. Particle Works’ …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 4 – Capsules
January 11 – Excipients